Literature DB >> 12446011

VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells.

Xiuju Jiang1, Huie Jing, Doina Ganea.   

Abstract

The immunoregulatory neuropeptides VIP and PACAP favor Th2-type immune responses. Antigen-stimulated Th2 cells produce VIP, VIP/PACAP induce Th2 cytokine responses, and promote the preferential survival of Th2 effectors. In this study, we investigate the effects of VIP/PACAP on two chemokines, i.e. CXCL10 (IP-10) acting on CXCR3 expressed on activated Th1 cells, and CCL22 (MDC) acting on CCR4 and 8 expressed on activated Th2 cells. VIP and PACAP down-regulate CXCL10, and up-regulate CCL22 in vivo and in vitro. The effects on the two chemokines appear to be different in mechanistic terms. The fact that VIP/PACAP might promote the directed migration of Th2 cells adds a new dimension to their participation in the Th2 auto-regulatory loop.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12446011     DOI： 10.1016/s0165-5728(02)00365-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

2.  Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Authors:  Sheri Tinnell Dorsam; Emilie Vomhof-Dekrey; Rebecca J Hermann; Jodie S Haring; Travis Van der Steen; Erich Wilkerson; Goran Boskovic; James Denvir; Yulia Dementieva; Donald Primerano; Glenn Paul Dorsam
Journal:  Mol Immunol       Date:  2010-02-01       Impact factor: 4.407

3.  Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis.

Authors:  Catalina Abad; Yossan-Var Tan; Robert Lopez; Hiroko Nobuta; Hongmei Dong; Phu Phan; Ji-Ming Feng; Anthony T Campagnoni; James A Waschek
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-26       Impact factor: 11.205

4.  Differential expression of chemokine receptors on human IgA+ and IgG+ B cells.

Authors:  C Johansson; I Ahlstedt; S Furubacka; E Johnsson; W W Agace; M Quiding-Järbrink
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 5.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.

Authors:  D Ganea; K M Hooper; W Kong
Journal:  Acta Physiol (Oxf)       Date:  2014-12-11       Impact factor: 6.311

Review 6.  Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

Authors:  David Pozo; Elena Gonzalez-Rey; Alejo Chorny; Per Anderson; Nieves Varela; Mario Delgado
Journal:  Peptides       Date:  2007-04-20       Impact factor: 3.750

Review 7.  Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.

Authors:  Elena Gonzalez-Rey; Per Anderson; Mario Delgado
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

8.  Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses.

Authors:  Y Wang; Y Mei; S Bao; L Xu
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

9.  Differential actions of pituitary adenylyl cyclase-activating polypeptide and interferon gamma on Th2- and Th1-associated chemokine expression in cultured murine microglia.

Authors:  Derek A Wainwright; Junping Xin; Virginia M Sanders; Kathryn J Jones
Journal:  J Neurodegener Regen       Date:  2008-10-01

Review 10.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.